NESS ZIONA, Israel, Aug. 17, 2024 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update.
Q2 2024 and Recent Corporate Developments
Mr. Mori Arkin, Executive Chairman of Sol-Gel, stated: “We are encouraged by Sol-Gel’s financial results for the second quarter of 2024 and our ability to extend our cash runway into the first quarter of 2026. We will continue to explore opportunities for non-dilutive funding to potentially further extend our runway through topline results. In our pipeline, we continue to conduct the pivotal Phase 3 clinical trial of SGT-610 for preventing new basal cell carcinomas in Gorlin Syndrome patients, targeting a market exceeding $300 million, with top line results anticipated in the second quarter of 2026 along with our proof-of-concept study for SGT-210 (topical erlotinib) in Darier disease patients targeting a market of between $200 million to $300 million. These two rare disease projects reflect the huge growth potential of a company of our size. The Sol-Gel management team and I are committed to spare no effort to realize this potential”.
Financial Results for the Second Quarter 2024
Total revenue in the second quarter was $5.4 million, which primarily consisted of licensing revenue from Beimei, Galderma and Searchlight, compared to $0.6 million revenues for the same period in 2023.
Research and development expenses were $2.4 million compared to $5.3 million for the same period in 2023. The decrease of $2.9 million was primarily attributed to a decrease of $0.7 million in manufacturing expenses related to TWYNEO, a decrease of $0.7 million in clinical development expenses related to a generic product candidate, a decrease of $0.5 million in payroll expenses due to the adoption of cost saving measures initiated during the third quarter of 2023, a decrease of $0.5 million related to R&D expenses, a decrease of $0.3 million in clinical trial expenses related to SGT-610 and a decrease of $0.2 million in clinical expenses related to SGT-210.
General and administrative expenses were $1.4 million compared to $1.8 million for the same period in 2023. The decrease of $0.4 million was mainly attributed to a decrease in professional expenses.
Sol-Gel reported a net income of $1.9 million for the second quarter of 2024 and earnings of $0.07 per basic and diluted share, compared to a net loss of $6.0 million and a loss of $0.22 per basic and diluted share for the same period in 2023.
As of June 30, 2024, Sol-Gel had $15.6 million in cash, cash equivalents, and deposits and $14.9 million in marketable securities for a total balance of $30.5 million. The Company expects its cash resources to fund cash requirements into the first quarter of 2026.
About TWYNEO and EPSOLAY
TWYNEO is a topical cream containing a fixed-dose combination of tretinoin, 0.1%, and benzoyl peroxide, 3%, cream for the treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. TWYNEO is the first acne treatment that contains a fixed-dose combination of benzoyl peroxide and tretinoin. Tretinoin and benzoyl peroxide are widely prescribed separately for acne vulgaris; however, benzoyl peroxide causes degradation of the tretinoin molecule, thereby potentially reducing its effectiveness if used at the same time or combined in the same formulation. TWYNEO uses silica (silicon dioxide) core shell structures to separately micro-encapsulate tretinoin crystals and benzoyl peroxide crystals enabling inclusion of the two active ingredients in the cream.
EPSOLAY is a topical cream containing benzoyl peroxide (BPO), 5%, for the treatment of bumps and blemishes (inflammatory lesions) of rosacea in adults. EPSOLAY utilizes a proprietary, patented technology to encapsulate BPO within silica-based microcapsules to create a barrier between the medication and the skin. The silica-based shell is designed to slowly release BPO over time to provide a tolerable and effective treatment.
About Gorlin Syndrome and SGT-610
SGT-610, a hedgehog signaling pathway blocker, has the potential to be the first ever treatment for prevention of BCCs in Gorlin syndrome patients, if approved. Gorlin syndrome, an autosomal dominant genetic disorder affecting approximately 1 in 27,000-31,000 people in the U.S., is mostly caused by inheritance of one defective copy of the tumor suppressor patched homolog 1 (PTCH1) gene. Normally, the PTCH1 gene blocks the smoothened, frizzle class receptor (SMO) gene, turning off the hedgehog signaling pathway when it is not needed. Mutations in the PTCH1 gene may cause a loss of PTCH1 function, release of SMO, and may allow BCC tumor cells to divide uncontrollably. Patidegib, the active substance in SGT-610, is designed to block the SMO signal, thus, allowing cells to function normally and reducing the production of new tumors.
About Darier Disease and SGT-210
SGT-210 is a topical erlotinib drug candidate that is formulated for the treatment of Darier Disease and other hyperkeratosis-related indications. Erlotinib is a tyrosine kinase receptor inhibitor that acts on the epidermal growth factor receptor, a protein present on cell surfaces that plays a key role in promoting cell growth and division. Darier Disease is a rare, genetic keratinization disorder which is classically characterized scaly crusted papules in a seborrheic distribution and in skin folds.
About Sol-Gel Technologies
Sol-Gel Technologies, Ltd. is a dermatology company focused on identifying, developing and commercializing or partnering drug products to treat skin diseases. Sol-Gel developed TWYNEO which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults.
The Company’s pipeline also includes Phase 3 clinical trial of Orphan and breakthrough drug candidate SGT-610, which is a new topical hedgehog inhibitor being developed to prevent the new basal cell carcinoma lesions in patients with Gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog inhibitors as well as topical drug candidate SGT-210 under investigation for the treatment of rare hyper keratinization disorders.
For additional information, please visit our new website: www.sol-gel.com
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to the amounts to be received under our current and future licensing agreements and our agreement with Padagis with respect to the generic drug product to Zoryve® Cream (roflumilast cream, 0.3%), the out-licensing Twyneo and Epsolay in additional territories, our expected cash runway, the expected royalties amounts to be received from Galderma, the potential of Sol-Gel’s assets including Twyneo, Epsolay, SGT-610, and SGT-210, the timeline for advancing SGT-610 and SGT-210, and the size of SGT-610’s market. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management’s current expectations and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, our ability to enter into further collaborations, lower than anticipated annual revenue income from new collaborations, a delay in the timing of our clinical trials, the success of our clinical trials, and an increase in our anticipated costs and expenses, as well as the following factors: (i) the adequacy of our financial and other resources, particularly in light of our history of recurring losses and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; (ii) our ability to complete the development of our product candidates; (iii) our ability to find suitable co-development partners; (iv) our ability to obtain and maintain regulatory approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; (v) our collaborators’ ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain adequate protection of our intellectual property; (vii) our collaborators’ ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; (viii) our collaborators’ ability to establish adequate sales, marketing and distribution channels; (ix) acceptance of our product candidates by healthcare professionals and patients; (x) the possibility that we may face third-party claims of intellectual property infringement; (xi) the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; (xii) intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; (xiii) potential product liability claims; (xiv) potential adverse federal, state and local government regulation in the United States, China, Europe or Israel; and (xv) loss or retirement of key executives and research scientists; (xvi) general market, political and economic conditions in the countries in which the Company operates; and, (xvii) the current war between Israel and Hamas and any deterioration of the war in Israel into a broader regional conflict involving Israel with other parties. These factors and other important factors discussed in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 13, 2024, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Except as required by law, we undertake no obligation to update any forward-looking statements in this press release.
Sol-Gel Contact:
Eyal Ben-Or
Chief Financial Officer
info@sol-gel.com
+972-8-9313429
Source: Sol-Gel Technologies Ltd.
SOL-GEL TECHNOLOGIES LTD. | ||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
(U.S. dollars in thousands, except share and per share data) | ||||||||
(Unaudited) | ||||||||
December 31, | June 30, | |||||||
2023 | 2024 | |||||||
Assets | ||||||||
CURRENT ASSETS: | ||||||||
Cash and cash equivalents | $ | 7,513 | $ | 11,549 | ||||
Bank deposits | 10,012 | 4,012 | ||||||
Marketable securities | 20,471 | 14,912 | ||||||
Accounts receivables | 377 | 6,059 | ||||||
Prepaid expenses and other current assets | 2,794 | 1,750 | ||||||
TOTAL CURRENT ASSETS | 41,167 | 38,282 | ||||||
NON-CURRENT ASSETS: | ||||||||
Restricted long-term deposits and cash equivalents | 1,284 | 1,273 | ||||||
Property and equipment, net | 434 | 305 | ||||||
Operating lease right-of-use assets | 1,721 | 1,507 | ||||||
Other long-term assets | 55 | 34 | ||||||
Funds in respect of employee rights upon retirement | 626 | 604 | ||||||
TOTAL NON-CURRENT ASSETS | 4,120 | 3,723 | ||||||
TOTAL ASSETS | $ | 45,287 | $ | 42,005 | ||||
Liabilities and shareholders’ equity | ||||||||
CURRENT LIABILITIES: | ||||||||
Accounts payable | $ | 154 | $ | 679 | ||||
Other accounts payable | 3,921 | 4,147 | ||||||
Current maturities of operating leases | 447 | 376 | ||||||
TOTAL CURRENT LIABILITIES | 4,522 | 5,202 | ||||||
LONG-TERM LIABILITIES | ||||||||
Operating leases liabilities | 1,206 | 1,018 | ||||||
Liability for employee rights upon retirement | 915 | 883 | ||||||
TOTAL LONG-TERM LIABILITIES | 2,121 | 1,901 | ||||||
TOTAL LIABILITIES | 6,643 | 7,103 | ||||||
SHAREHOLDERS’ EQUITY: | ||||||||
Ordinary Shares, NIS 0.1 par value – authorized: 50,000,000 as of December 31, 2023 and June 30, 2024; issued and outstanding: 27,857,620 as of December 31, 2023 and June 30, 2024. | 774 | 774 | ||||||
Additional paid-in capital | 258,173 | 258,799 | ||||||
Accumulated deficit | (220,303) | (224,671) | ||||||
TOTAL SHAREHOLDERS’ EQUITY | 38,644 | 34,902 | ||||||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 45,287 | $ | 42,005 | ||||
SOL-GEL TECHNOLOGIES LTD. | |||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||
(U.S. dollars in thousands, except share and per share data) | |||||||||||
(Unaudited) | |||||||||||
Six months ended | Three months ended | ||||||||||
June 30 |
June 30 | ||||||||||
2023 | 2024 | 2023 | 2024 | ||||||||
REVENUE | $ | 894 | $ | 5,899 | $ | 594 | $ | 5,433 | |||
RESEARCH AND DEVELOPMENT EXPENSES | 14,698 | 7,783 | 5,312 | 2,438 | |||||||
GENERAL AND ADMINISTRATIVE EXPENSES | 3,786 | 3,203 | 1,809 | 1,371 | |||||||
OPERATING INCOME (LOSS) | $ | (17,590) | $ | (5,087) | $ | (6,527) | $ | 1,624 | |||
FINANCIAL INCOME, net | 899 | 719 | 557 | 352 | |||||||
NET INCOME (LOSS) FOR THE PERIOD | $ | (16,691) | $ | (4,368) | $ | (5,970) | $ | 1,976 | |||
BASIC AND DILUTED EARNINGS (LOSS) PER | |||||||||||
ORDINARY SHARE | $ | (0.63) | $ | (0.16) | $ | (0.22) | $ | 0.07 | |||
WEIGHTED AVERAGE NUMBER OF SHARES | |||||||||||
OUTSTANDING USED IN COMPUTATION OF | |||||||||||
BASIC AND DILUTED LOSS PER SHARE | 26,306,484 | 27,857,620 | 27,660,326 | 27,857,620 |
NEW YORK CITY, NY / ACCESSWIRE / August 18, 2024 / PM360, a monthly magazine…
BEIJING, Aug. 18, 2024 /PRNewswire/ -- On August 10, the third press conference for the…
CHERRY HILL, NJ / ACCESSWIRE / August 17, 2024 / LifeRx, a leading provider of…
COPENHAGEN, Denmark, August 17, 2024 – Bavarian Nordic A/S (OMX: BAVA) provides an update on…
Dartmouth, Nova Scotia--(Newsfile Corp. - August 17, 2024) - Matty Renos, a leading renovation and…
The pilot project partnership envisions breath diagnostics to be an in-home screening that is fast,…